Alzheimer's Disease and Related Disorders

NCT01315704 | Unknown

• 1 other identifier: 2009-15
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare characteristics of gait and balance measured among patients with Alzheimer's disease or related disorders separated into 3 groups according to the stage of disease (i.e., pre-dementia, mild and moderate dementia stages); to determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities; and to establish a database at Angers University Memory Centre.

Conditions

Alzheimer's Disease; Gait Apraxia; Impaired Cognition

Outcome Measures

Primary Outcomes (1)

• Spatiotemporal gait parameters

  baseline

Study Arms (3)

Group 1

Patients with Mild Cognitive Impairment

Drug: Drug intervention

Group 2

Patients with Mild Alzheimer's disease or related disorders

Drug: Drug intervention

Group 3

Patients with Moderate Alzheimer's disease or related disorders

Drug: Drug intervention

Interventions

Drug intervention DRUG

before-after interventional (anti-dementia drugs and/or vitamin D) study

Also known as: Anti-dementia drugs and/or vitamin D

Group 1; Group 2; Group 3

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All patients of the University Memory Center of Angers University Hospital with respect to the eligibility criteria

You may qualify if:

• All elderly patients from the University Memory Center of Angers University Hospital.
• Able to walk without any walking aid on 15 meters
• Mini-Mental Status Examination score \> 10
• Being affiliated to a social security regime

You may not qualify if:

• Mini-Mental Status Examination score ≤ 10
• Subject suffering from pre-existing impellent disturbances
• History of cerebrovascular accident or other cerebro-spinal pathology
• Poor workmanship of the written or oral French language
• Use of walking aid such as walking frame with wheels or tricycle.
• Acute medical or surgical disease in the past 3 months
• Refusal to participate (or trustworthy person)
• Near visual acuity \< 2/10

Sponsors & Collaborators

• University Hospital, Angers: lead

Study Sites (1)

Cédric ANNWEILER , MD

Angers, 49933, France

RECRUITING

Related Publications (2)

• Beauchet O, Barden J, Liu-Ambrose T, Chester VL, Annweiler C, Szturm T, Grenier S, Leonard G, Bherer L, Allali G; Canadian Gait Consortium. Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial. Drugs Aging. 2016 Sep;33(9):665-73. doi: 10.1007/s40266-016-0391-0.

  PMID: 27568453 DERIVED

• Beauchet O, Launay CP, Allali G, Watfa G, Gallouj K, Herrmann FR, Annweiler C. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurol. 2013 Nov 21;13:184. doi: 10.1186/1471-2377-13-184.

  PMID: 24261605 DERIVED

MeSH Terms

Conditions

Alzheimer Disease; Gait Apraxia; Cognition Disorders

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Gait Disorders, Neurologic; Neurologic Manifestations; Apraxias; Psychomotor Disorders; Neurobehavioral Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Cedric ANNWEILER, MD

  Memory Centre of Angers University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Cedric ANNWEILER, DM

CONTACT

(+33) 241354725; ceannweiler@chu-angers.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: March 11, 2011
• First Posted: March 15, 2011
• Study Start: November 1, 2009
• Primary Completion: November 1, 2017
• Study Completion: November 1, 2017
• Last Updated: March 15, 2011

Record last verified: 2011-03

Locations

FR (1)